about
Targeted drugs in small-cell lung cancerPhase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.Small cell lung cancer: will recent progress lead to improved outcomes?Lung cancer in the era of precision medicineEvolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyMicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges.Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer.Recent developments in the use of immunotherapy in non-small cell lung cancer.Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer.Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.A case report of tongue metastasis from lung squamous cell carcinoma and literature review.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.Molecular biology tools for precision medicine in managing lung cancer.5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.Advanced small cell lung cancer (SCLC): new challenges and new expectations.Drug resistance profiles of mutations in the RET kinase domain
P2860
Q26767017-D4CECE4C-20B8-4D5E-B33D-BDCE0FE81982Q33275887-711C804F-D5BD-4467-9A76-288C3335DC87Q35836257-A7B1FA3D-B4CE-4EE2-B9AF-BE08B193243AQ35861107-A9DAB2DC-4F9C-41F6-9D26-D05E86E908CAQ37666880-2F4FD537-8944-4168-B80D-7CC08ADAE297Q38598893-DA87526A-CAA4-4CA0-A60E-BF9480AD6715Q38616261-BE0DE918-A3A5-4056-9633-6E8A47CF1996Q38663460-E5099A5D-D4FC-4CA6-9D86-9AA5BF215699Q38665438-345B35D6-4A1F-4715-987C-C9386328F69DQ38734500-504CE155-0CC4-4848-8336-4FAC95BA8090Q38753582-5127F510-16F5-47D2-8548-B6946D85E5A8Q38801383-45A79302-2E16-40F3-81E0-6E74580897BFQ38826419-A76DD8A7-79B4-446A-A11C-B92158EA191BQ39254692-0AB88E49-B9C5-4B8F-BB7B-FF822E513FF1Q39430016-F76173DF-7E38-4FDD-930D-878C6A48AB0DQ47152410-413C5691-F228-4095-B042-E29397A3EE8EQ47260594-48F395E1-7CD8-4D87-8E14-6CCD7C6DBF17Q49658290-364126ED-F00D-44A5-9145-AE17E5591BCBQ52584335-770126C6-7523-4199-B0F0-E18AA85C0C0CQ53217202-9C272CE3-939E-416E-B78D-2653E88BCD90Q53394177-50C6BB35-DE2C-46E1-83A4-C177ACB705E3Q54977232-2DAA4CF0-5AAE-40C3-B238-5168D40749E6Q58044610-1A41B315-55C4-4467-8024-60D1669FD9F8
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@ast
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@en
type
label
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@ast
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@en
prefLabel
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@ast
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@en
P2860
P1476
EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
@en
P2093
Gregory J Riely
Helena A Yu
P2860
P304
P356
10.1158/1078-0432.CCR-14-3154
P407
P577
2015-05-01T00:00:00Z